MENU
+Compare
BCYC
Stock ticker: NASDAQ
AS OF
Jun 20, 04:59 PM (EDT)
Price
$7.42
Change
+$0.01 (+0.13%)
Capitalization
513.17M

BCYC Bicycle Therapeutics plc Forecast, Technical & Fundamental Analysis

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles... Show more

BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BCYC with price predictions
Jun 18, 2025

BCYC sees MACD Histogram just turned negative

BCYC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on June 16, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BCYC as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

BCYC moved below its 50-day moving average on June 16, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCYC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for BCYC's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for BCYC crossed bullishly above the 50-day moving average on May 29, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BCYC advanced for three days, in of 259 cases, the price rose further within the following month. The odds of a continued upward trend are .

BCYC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 152 cases where BCYC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.693) is normal, around the industry mean (17.006). P/E Ratio (0.000) is within average values for comparable stocks, (59.274). BCYC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.273). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (18.692) is also within normal values, averaging (256.503).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BCYC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BCYC is expected to report earnings to rise 6.82% to -93 cents per share on July 31

Bicycle Therapeutics plc BCYC Stock Earnings Reports
Q2'25
Est.
$-0.94
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.11
Q3'24
Beat
by $0.06
Q2'24
Beat
by $0.36
The last earnings report on May 01 showed earnings per share of -87 cents, missing the estimate of -85 cents. With 115.71K shares outstanding, the current market capitalization sits at 513.17M.
A.I. Advisor
published General Information

General Information

a holding company, which engages in the development of biopharmaceuticals.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Granta Park, Great Abington
Phone
+44 1223261503
Employees
284
Web
https://www.bicycletherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OISGX13.350.05
+0.38%
Optimum Small-Mid Cap Growth Instl
RDWGX12.12N/A
N/A
American Funds Dvlpg Wld Gr&Inc R6
STCZX16.02-0.03
-0.19%
Virtus Silvant Large-Cap Growth Stk R6
PLGIX16.90-0.06
-0.35%
Principal LargeCap Growth I Instl
VLEQX11.07-0.06
-0.54%
Villere Equity

BCYC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with INO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
-3.01%
INO - BCYC
57%
Loosely correlated
+2.63%
XNCR - BCYC
55%
Loosely correlated
+0.60%
RPTX - BCYC
51%
Loosely correlated
-0.70%
RLAY - BCYC
50%
Loosely correlated
+9.80%
RCUS - BCYC
45%
Loosely correlated
-2.18%
More